Medicine

A disorganized rollout has presented some people with that ethical quandary. WHYY’s Health Desk Help Desk heard several points of view.

How pharmacy benefit managers impacted one independent pharmacist.

Some Delawareans who got their first vaccine shot a few weeks ago have been panicking, because they haven’t been able to schedule their second dose.

City officials are encouraged by the overall decline in case counts, but they are still urging people not to let their guard down.

Scientists say vaccinations need to be as fast as possible to prevent more contagious coronavirus variants from taking over.

Caregivers must take steps to make sure those with limited communication and social skills stay safe because other conditions put them at higher risk.

It’s hard to pin down a specific answer for any one person. WHYY’s Health Desk Help Desk created this interactive way to figure out where you stand.

Maria Kefalas discusses her memoir about coping with her daughter Calliope's terminal illness and how she learned to turn her grief into action and advocacy.

The federal government has allocated 5.8 million Moderna doses to states this week, according to the latest data from the Centers for Disease Control and Prevention.

Dr. Paul Stoffels, the chief scientific officer at Johnson & Johnson, said the company's vaccine is effective where it matters most: preventing hospitalizations and deaths.

The disclosures could threaten public confidence in a national rollout already marked by vaccine shortages, appointment logjams and inconsistent standards state to state.

J&J said Friday that in the U.S. and seven other countries, the single-shot vaccine was 66% effective overall at preventing moderate to severe illness.

High rates of heart disease have meant higher COVID-19 infection rates for Black Americans. A pilot program aims to provide mentorship to medical trainees.

The administration says it plans to buy an additional 100 million doses each from both Moderna and from Pfizer, which has a vaccine with its German counterpart BioNTech.

Penn, Temple and Einstein are pivoting from Phase 1A, when they vaccinated their patient-facing staff, to Phase 1B, their most at-risk patients.